Amgen To Highlight Extensive Long-Term Safety And Efficacy Data Of Aimovig ® (erenumab-aooe) Across The Spectrum Of Migraine At AAN Annual Meeting

After Long-Term Aimovig Treatment, Two-Thirds of Chronic Migraine Patients Converted to Episodic Migraine, Experiencing 11 Fewer Migraine Days per Month on Average Separate Study Showed the Majority of Episodic Migraine Patients on Aimovig Reported at Least a 50 Percent Reduction in Monthly Migraine Days at One Year, With One in Five Being Completely Migraine-Free Aimovig is the Most Prescribed Anti-CGRP Therapy - Approximately 200,000 Patients in the U.S. Have Been Prescribed Aimovig Since Launch[1] THOUSAND OAKS, Calif., May 2, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will present new long-term data of Aimovig® (erenumab-aooe) across the migraine spectrum a...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news